Last 12 months
Inside the activity.
6 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 4 | 0 |
| Dec 2025 | 2 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2025 Filed Dec 16, 2025 23:34 UTC |
Weisblum EricDirector · Chief Executive Officer
|
PurchaseCommon Stock | 2,500 | $0.42 | $1,050.00 |
DisclosureSEC source: 0001213900-25-122429 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,932 Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 23:34 UTC |
Weisblum EricDirector · Chief Executive Officer
|
PurchaseCommon Stock | 2,500 | $0.41 | $1,025.00 |
DisclosureSEC source: 0001213900-25-122429 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,432 Read SEC document |
| November 21, 2025 Filed Nov 21, 2025 23:35 UTC |
Weisblum EricDirector · Chief Executive Officer
|
PurchaseCommon Stock | 1,000 | $0.37 | $365.00 |
DisclosureSEC source: 0001213900-25-113743 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,932 Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 23:35 UTC |
Weisblum EricDirector · Chief Executive Officer
|
PurchaseCommon Stock | 1,000 | $0.37 | $370.00 |
DisclosureSEC source: 0001213900-25-113743 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,932 Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 21:00 UTC |
Weisblum EricDirector · Chief Executive Officer
|
PurchaseCommon Stock | 4,500 | $0.41 | $1,822.50 |
DisclosureSEC source: 0001213900-25-113104 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,932 F2 · price: This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 19, 2025 at prices ranging from $0.3975 to $0.4100. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:00 UTC |
Weisblum EricDirector · Chief Executive Officer
|
PurchaseCommon Stock | 7,500 | $0.40 | $3,024.75 |
DisclosureSEC source: 0001213900-25-113104 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,432 F1 · price: This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 18, 2025 at prices ranging from $0.4000 to $0.4050. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2025 Filed May 28, 2025 20:30 UTC |
Weisblum EricDirector · Chief Executive Officer
|
PurchaseCommon Stock | 10,000 | $0.43 | $4,329.00 |
DisclosureSEC source: 0001213900-25-048304 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,932 F1 · price: This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions at prices ranging from $0.42 to $0.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2025 Filed May 27, 2025 23:03 UTC |
Linsley WayneDirector
|
GrantOptions (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001213900-25-047915 · ownership.xml · derivative · entry 1 Linsley Wayne · CIK 0001809972 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,425 Underlying: Common Stock · 50,000 shares Expires 2035-05-23 F1 · kind: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. Read SEC document |
| May 23, 2025 Filed May 27, 2025 19:02 UTC |
Ryweck Daniel E.Chief Financial Officer
|
GrantOptions (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001213900-25-047913 · ownership.xml · derivative · entry 1 Ryweck Daniel E. · CIK 0001652799 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-23 F1 · kind: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. Read SEC document |
| May 23, 2025 Filed May 27, 2025 23:03 UTC |
Munoz KevinDirector
|
GrantOptions (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001213900-25-047914 · ownership.xml · derivative · entry 1 Munoz Kevin · CIK 0001847763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,425 Underlying: Common Stock · 50,000 shares Expires 2035-05-23 F1 · kind: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. Read SEC document |
| May 23, 2025 Filed May 27, 2025 23:02 UTC |
Weisblum EricDirector · Chief Executive Officer
|
GrantOptions (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001213900-25-047912 · ownership.xml · derivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,932 Underlying: Common Stock · 200,000 shares Expires 2035-05-23 F1 · kind: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. Read SEC document |
| May 23, 2025 Filed May 27, 2025 23:00 UTC |
Pavell JeffDirector
|
GrantOptions (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001213900-25-047910 · ownership.xml · derivative · entry 1 Pavell Jeff · CIK 0001840601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-23 F1 · kind: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 22:00 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 2,500 | $0.84 | $2,096.75 |
DisclosureSEC source: 0001213900-24-109363 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,932 Read SEC document |
| November 22, 2024 Filed Nov 22, 2024 21:16 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 2,500 | $0.90 | $2,250.00 |
DisclosureSEC source: 0001213900-24-101610 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,432 Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:16 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 2,500 | $0.95 | $2,375.00 |
DisclosureSEC source: 0001213900-24-101610 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,932 Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 17:19 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 4,438 | $1.11 | $4,926.18 |
DisclosureSEC source: 0001213900-24-052354 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,432 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.12. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 17:19 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 562 | $1.08 | $606.96 |
DisclosureSEC source: 0001213900-24-052354 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,994 Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 20:00 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 400 | $2.03 | $812.00 |
DisclosureSEC source: 0001213900-24-031159 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,432 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.05. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 20:00 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 600 | $1.96 | $1,176.00 |
DisclosureSEC source: 0001213900-24-031159 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,032 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.96 to $1.97. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 01, 2024 Filed Apr 1, 2024 22:15 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 1,100 | $1.91 | $2,101.00 |
DisclosureSEC source: 0001213900-24-028973 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,432 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $1.93. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 22:15 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 3,408 | $1.94 | $6,611.52 |
DisclosureSEC source: 0001213900-24-028973 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,332 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.91 to $1.95. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 21:13 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 200 | $1.61 | $322.00 |
DisclosureSEC source: 0001213900-23-097689 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,924 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.60 to $1.63. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:13 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 500 | $1.63 | $815.00 |
DisclosureSEC source: 0001213900-23-097689 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,724 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.61 to $1.65. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 00:44 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 900 | $1.52 | $1,368.00 |
DisclosureSEC source: 0001213900-23-096606 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,224 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.52. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 14, 2023 Filed Dec 19, 2023 00:44 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 200 | $1.50 | $300.00 |
DisclosureSEC source: 0001213900-23-096606 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,324 Read SEC document |
| December 07, 2023 Filed Dec 7, 2023 23:13 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 324 | $1.36 | $440.64 |
DisclosureSEC source: 0001213900-23-094145 · ownership.xml · nonDerivative · entry 3 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,124 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.34 to $1.40. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 23:13 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 76 | $1.34 | $101.84 |
DisclosureSEC source: 0001213900-23-094145 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,800 Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 23:13 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 600 | $1.39 | $834.00 |
DisclosureSEC source: 0001213900-23-094145 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,724 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.40. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 02:10 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 1,000 | $1.53 | $1,530.00 |
DisclosureSEC source: 0001213900-23-091665 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,124 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.52 to $1.55. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 02:10 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 1,000 | $1.57 | $1,570.00 |
DisclosureSEC source: 0001213900-23-091665 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,124 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.56 to $1.57. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 27, 2023 Filed Nov 27, 2023 22:13 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 250 | $1.78 | $445.00 |
DisclosureSEC source: 0001213900-23-090270 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,124 Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 22:13 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 400 | $1.68 | $672.00 |
DisclosureSEC source: 0001213900-23-090270 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,874 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.64 to $1.70. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 21:01 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 300 | $1.56 | $468.00 |
DisclosureSEC source: 0001213900-23-089570 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,474 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:01 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 4,050 | $1.60 | $6,480.00 |
DisclosureSEC source: 0001213900-23-089570 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,174 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.57 to $1.65. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 00:51 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 1,800 | $1.54 | $2,772.00 |
DisclosureSEC source: 0001213900-23-088890 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,124 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $1.60. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 00:51 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 1,100 | $1.33 | $1,463.00 |
DisclosureSEC source: 0001213900-23-088890 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,324 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.24 to $1.46. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 26, 2023 Filed May 26, 2023 16:17 UTC |
Ryweck Daniel E.Chief Financial Officer
|
PurchaseCommon Stock | 1,000 | $2.13 | $2,126.40 |
DisclosureSEC source: 0001213900-23-043531 · ownership.xml · nonDerivative · entry 1 Ryweck Daniel E. · CIK 0001652799 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 18, 2023 Filed May 18, 2023 20:15 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 500 | $2.11 | $1,053.50 |
DisclosureSEC source: 0001213900-23-041179 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,724 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at $2.104 and $2.109. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 17, 2023 Filed May 18, 2023 20:15 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 2,500 | $2.06 | $5,150.00 |
DisclosureSEC source: 0001213900-23-041179 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,224 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.000 to $2.0899. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 00:07 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 130 | $2.72 | $353.60 |
DisclosureSEC source: 0001213900-22-081513 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,854 Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 00:07 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 200 | $2.68 | $536.30 |
DisclosureSEC source: 0001213900-22-081513 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,724 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.65 to $2.713. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 21:15 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 263 | $3.17 | $833.68 |
DisclosureSEC source: 0001213900-22-080102 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,524 Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:15 UTC |
Weisblum EricDirector · CEO and President
|
PurchaseCommon Stock | 487 | $3.07 | $1,493.92 |
DisclosureSEC source: 0001213900-22-080102 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,261 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.992 to $3.20. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 12:05 UTC |
Weisblum EricDirector · CEO, CFO and President
|
PurchaseCommon Stock | 13,080 | $0.11 | $1,500.28 |
DisclosureSEC source: 0001213900-22-033752 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · CEO, CFO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,724,643 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1302 to $0.11. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 29, 2021 Filed Jan 4, 2022 02:55 UTC |
Linsley WayneDirector
|
GrantNon-Qualified Stock Option · Derivative | 171,233 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001213900-22-000364 · ownership.xml · derivative · entry 2 Linsley Wayne · CIK 0001809972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,466 Underlying: Common Stock · 171,233 shares Expires 2026-12-29 F2 · price: The options were issued under the issuer's 2020 Omnibus Equity Incentive Plan. F1 · derivative.underlying_shares: Vests over the course of one year from grant with 100% vesting a year from the date of grant. Read SEC document |
| December 29, 2021 Filed Jan 4, 2022 02:55 UTC |
Linsley WayneDirector
|
GrantNon-Qualified Stock Option · Derivative | 171,233 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001213900-22-000364 · ownership.xml · derivative · entry 1 Linsley Wayne · CIK 0001809972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,233 Underlying: Common Stock · 171,233 shares Expires 2026-12-29 F2 · price: The options were issued under the issuer's 2020 Omnibus Equity Incentive Plan. F1 · derivative.underlying_shares: Vests over the course of one year from grant with 100% vesting a year from the date of grant. Read SEC document |
| December 29, 2021 Filed Jan 4, 2022 02:55 UTC |
Munoz KevinDirector
|
GrantNon-Qualified Stock Option · Derivative | 171,233 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001213900-22-000363 · ownership.xml · derivative · entry 1 Munoz Kevin · CIK 0001847763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,233 Underlying: Common Stock · 171,233 shares Expires 2026-12-29 F2 · price: The options were issued under the issuer's 2020 Omnibus Equity Incentive Plan. F1 · derivative.underlying_shares: Vests over the course of one year from grant with 100% vesting a year from the date of grant. Read SEC document |
| December 29, 2021 Filed Jan 5, 2022 23:18 UTC Amendment |
Linsley WayneDirector
|
GrantNon-Qualified Stock Option · Derivative | 171,233 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001213900-22-000777 · ownership.xml · derivative · entry 1 Linsley Wayne · CIK 0001809972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,233 Underlying: Common Stock · 171,233 shares Expires 2026-12-29 F3 · security: This Form 4/A deletes the second Non-Qualified Stock Option for 171,233 shares erroneously reported in the original Form 4 filed on January 3, 2022. F2 · price: The options were issued under the issuer's 2020 Omnibus Equity Incentive Plan. F1 · derivative.underlying_shares: Vests over the course of one year from grant with 100% vesting a year from the date of grant. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 18:31 UTC |
Weisblum EricDirector · Chief Executive Officer
|
PurchaseCommon Stock | 17,500 | $0.14 | $2,409.75 |
DisclosureSEC source: 0001213900-21-065395 · ownership.xml · nonDerivative · entry 2 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,711,563 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.131 to $0.1455. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 18:31 UTC |
Weisblum EricDirector · Chief Executive Officer
|
PurchaseCommon Stock | 5,000 | $0.16 | $777.00 |
DisclosureSEC source: 0001213900-21-065395 · ownership.xml · nonDerivative · entry 1 Weisblum Eric · CIK 0001569077 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,694,063 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.